Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 2,130 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 2,130 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $19.52, for a total transaction of $41,577.60. Following the sale, the insider now directly owns 78,335 shares in the company, valued at approximately $1,529,099.20. This trade represents a 2.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Castle Biosciences Stock Performance

Shares of NASDAQ CSTL opened at $19.54 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. Castle Biosciences, Inc. has a one year low of $16.97 and a one year high of $35.84. The business’s 50-day moving average price is $26.31 and its two-hundred day moving average price is $28.83. The company has a market capitalization of $547.26 million, a P/E ratio of 97.70 and a beta of 0.98.

Institutional Investors Weigh In On Castle Biosciences

Several large investors have recently made changes to their positions in CSTL. Algert Global LLC lifted its stake in Castle Biosciences by 0.4% in the third quarter. Algert Global LLC now owns 134,321 shares of the company’s stock valued at $3,831,000 after acquiring an additional 599 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Castle Biosciences by 11.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company’s stock valued at $158,000 after purchasing an additional 604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Castle Biosciences by 4.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,786 shares of the company’s stock valued at $394,000 after purchasing an additional 608 shares during the last quarter. Invesco Ltd. boosted its holdings in Castle Biosciences by 2.3% in the fourth quarter. Invesco Ltd. now owns 27,534 shares of the company’s stock worth $734,000 after purchasing an additional 616 shares in the last quarter. Finally, Assetmark Inc. increased its position in Castle Biosciences by 16.8% during the third quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock worth $149,000 after buying an additional 748 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on CSTL shares. Stephens reissued an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. Robert W. Baird lifted their target price on Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Castle Biosciences presently has a consensus rating of “Buy” and an average target price of $40.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.